Sec Form 4 Filing - Reis James Richard @ Arcadia Biosciences, Inc. - 2016-07-09

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Reis James Richard 2. Issuer Name and Ticker or Trading Symbol Arcadia Biosciences, Inc. [ RKDA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 3333 LEE PARKWAY, SUITE 1200 3. Date of Earliest Transaction (MM/DD/YY) 07/09/2016 (Street) DALLAS, TX75219 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 50,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 2.24 ( 1 ) 12/31/2019 Common Stock 15,000 15,000 D Employee Stock Option (right to buy) $ 7.2 ( 2 ) 02/11/2015 Common Stock 5,000 5,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Reis James Richard 3333 LEE PARKWAY, SUITE 1200 DALLAS, TX75219 X Signatures /s/ James R. Reis 07/20/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Reporting Person resigned his position as a Director of Arcadia Biosciences, Inc. (the "Issuer") effective July 9, 2016 (the "Resignation Date"). As of the Resignation Date, the Reporting Person is no longer subject to Section 16 in connection with his transactions in the Issuer's equity securities and therefore will report only non-exempt transactions occurring within six months of opposite-way non-exempt transactions on future Forms 4 and 5. As of the Resignation Date, there were a total of 15,000 shares vested and exercisable pursuant to the Issuer's 2006Stock Plan and the applicable Stock Option Award Agreement. The vested options will remain exercisable for a period of thirty (30) days following the Resignation Date. ( 2 )As of the Resignation Date (as defined in Footnote 1), there were a total of 5,000 shares vested and exercisable pursuant to the Issuer's 2006 Stock Plan and the applicable Stock Option Award Agreement. The vested options will remain exercisable for a period of thirty (30) days following the Resignation Date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.